These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25387086)

  • 1. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
    Yang Y; Deng Y; Wen B; Wang H; Meng X; Lan J; Gao GF; Tan W
    Viral Immunol; 2014 Dec; 27(10):543-50. PubMed ID: 25387086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
    Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J
    Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MERS-CoV spike protein: Targets for vaccines and therapeutics.
    Wang Q; Wong G; Lu G; Yan J; Gao GF
    Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
    Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
    Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
    Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
    Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.
    Wang C; Hua C; Xia S; Li W; Lu L; Jiang S
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.
    Ma C; Wang L; Tao X; Zhang N; Yang Y; Tseng CK; Li F; Zhou Y; Jiang S; Du L
    Vaccine; 2014 Oct; 32(46):6170-6176. PubMed ID: 25240756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
    Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J
    Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.
    Kim J; Yang YL; Jang SH; Jang YS
    Virol J; 2018 Aug; 15(1):124. PubMed ID: 30089512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection.
    Jia W; Channappanavar R; Zhang C; Li M; Zhou H; Zhang S; Zhou P; Xu J; Shan S; Shi X; Wang X; Zhao J; Zhou D; Perlman S; Zhang L
    Emerg Microbes Infect; 2019; 8(1):760-772. PubMed ID: 31130102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
    Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
    Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
    Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bioinformatics-based Design of Peptide Vaccine Candidates Targeting Spike Protein of MERS-CoV and Immunity analysis in Mice].
    Lan J; Lu S; Deng Y; Wen B; Chen H; Wang W; Tan W
    Bing Du Xue Bao; 2016 Jan; 32(1):77-81. PubMed ID: 27295887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
    Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
    J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.